# TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma

> **NCT04988945** · PHASE2 · RECRUITING · sponsor: **The University of Hong Kong** · enrollment: 33 (estimated)

## Conditions studied

- HCC

## Interventions

- **PROCEDURE:** TACE
- **RADIATION:** SBRT
- **DRUG:** Durvalumab
- **DRUG:** Tremelimumab

## Key facts

- **NCT ID:** NCT04988945
- **Lead sponsor:** The University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-12-01
- **Primary completion:** 2024-12-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2023-09-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04988945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04988945, "TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04988945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*